<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04835870</url>
  </required_header>
  <id_info>
    <org_study_id>ZR-CHOP</org_study_id>
    <nct_id>NCT04835870</nct_id>
  </id_info>
  <brief_title>Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL</brief_title>
  <official_title>Zanubrutinib Combination With R-CHOP in Treating Patients With Newly Diagnosed Untreated Non-GCB DLBCL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this study will evaluate the efficacy and safety of zanubrutinib in combination with&#xD;
      R-CHOP for newly diagnosed untreated Non-GCB DLBCL Patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma.&#xD;
      According to Hans' algorithms, DLBCL can be identified as 2 subtypes: germinal&#xD;
      b-cell-like(GCB) and non-germinal b-cell-like(non-GCB). Approximately 50 to 60% of DLBCL was&#xD;
      non-GCB subtype DLBCL.The non-GCB DLBCL revealed poor clinical outcomes. Bruton's tyrosine&#xD;
      kinase (BTK) inhibitors have established therapeutic activity in B cell malignancies, with&#xD;
      potential activity in non-GCB DLBCL. This study will evaluate the efficacy and safety of&#xD;
      zanubrutinib in combination with R-CHOP for newly diagnosed untreated Non-GCB DLBCL Patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival(PFS)</measure>
    <time_frame>up to 18 months</time_frame>
    <description>To measure the duration of response to ZR-CHOP over a follow-up period of 18 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>up to 18 months</time_frame>
    <description>To measure the duration of response to ZR-CHOP over a follow-up period of 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Number of patients who achieved complete response after treatment by ZR-CHOP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Duration of overall response will be assessed from the first ZR-CHOP given to progression,death or last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 18 months</time_frame>
    <description>OS will be assessed from the first ZR-CHOP given to death or last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events profile</measure>
    <time_frame>Measured from start of treatment until 28 days after last dose</time_frame>
    <description>Number of participants with adverse events. Frequencies of toxicities based on the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 will be tabulated</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non-GCB/ABC Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>R-CHOP + Zanubrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zanubrutinib plus Rituximab, Cyclosphosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanubrutinib</intervention_name>
    <description>Zanubrutinib-160mg bid PO d0-d20(1-21d)</description>
    <arm_group_label>R-CHOP + Zanubrutinib</arm_group_label>
    <other_name>BTK inhibitors</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab-375 mg/m2 i.v d0 (/21d)</description>
    <arm_group_label>R-CHOP + Zanubrutinib</arm_group_label>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide-750 mg/m2 i.v d1 (/21d)</description>
    <arm_group_label>R-CHOP + Zanubrutinib</arm_group_label>
    <other_name>CTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin-50 mg/m2 i.v d1 (/21d)</description>
    <arm_group_label>R-CHOP + Zanubrutinib</arm_group_label>
    <other_name>ADM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine-1.4 mg/m2 i.v d1 (/21d)(2 mg max)</description>
    <arm_group_label>R-CHOP + Zanubrutinib</arm_group_label>
    <other_name>VCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone-100 mg p.o d1-d5 (/21d)</description>
    <arm_group_label>R-CHOP + Zanubrutinib</arm_group_label>
    <other_name>Prednisonum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed Non-GCB DLBCL with extrinsic involvement&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. Measurable disease of at least 15mm(node)/10mm（extranodal）&#xD;
&#xD;
          4. ECOG performance status 0-2&#xD;
&#xD;
          5. Adequate organ function:Cardiac ejection fraction (EF) ≥ 50%;Creatinine clearance rate&#xD;
             (≥30 mL/min) of serum creatinine; Aspartate Aminotransferase (AST), Alanine&#xD;
             Aminotransferase (ALT) ≤3 times ULN&#xD;
&#xD;
          6. Adequate bone marrow function:Platelet count (≥ 50×10^9/L);Hemoglobin (≥ 8 g/dL);The&#xD;
             absolute value of neutrophils (≥1.0×10^9/L)&#xD;
&#xD;
          7. Estimated survival time ≥3 months&#xD;
&#xD;
          8. Subjects of child-bearing or child-fathering potential must be willing to practice&#xD;
             birth control from the time of enrollment on this study until the follow-up period of&#xD;
             the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Accepted major surgery within 4 weeks before treatment;&#xD;
&#xD;
          2. Diagnosis of primary mediastinal lymphoma or primary CNS lymphoma;&#xD;
&#xD;
          3. Previous history of indolent lymphoma;&#xD;
&#xD;
          4. Prior malignancy (other than DLBCL), except for cured malignant tumors with no active&#xD;
             lesions for 3 years;Adequate treatment of inactive lesions in non-melanoma skin cancer&#xD;
             、malignant tonsilloma or carcinoma in situ;&#xD;
&#xD;
          5. History of intracranial haemorrhage in preceding 6 months,requires or receiving&#xD;
             anticoagulation with warfarin or equivalent antagonists;&#xD;
&#xD;
          6. Requires treatment with a strong/medium CYP3A inducer;&#xD;
&#xD;
          7. The previous use of anthracycline-based drugs &gt; 150 mg/m2;&#xD;
&#xD;
          8. Evidence of complications or medical conditions, including but not limited, that may&#xD;
             interfere the conduct of the study or place the patient at serious risk:significant&#xD;
             cardiovascular disease(class 3 or 4 cardiac disease as defined by the New York Heart&#xD;
             Association Functional Classification、myocardial infarction within 6 months of&#xD;
             screening、uncontrolled or symptomatic arrhythmias) and/or significant lung disease;&#xD;
&#xD;
          9. HIV infection and/or active hepatitis B or active hepatitis C;&#xD;
&#xD;
         10. Uncontrolled systemic infection;&#xD;
&#xD;
         11. Pregnant or breasting-feeding women;&#xD;
&#xD;
         12. According to the researchers' judgment, patients' underlying condition may increase&#xD;
             their risk of receiving research drug treatment, or confuse their judgment on toxic&#xD;
             reactions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Depei Wu, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caixia Li, M.D</last_name>
    <phone>+86 512 67781856</phone>
    <email>licaixia@suda.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jia Chen, M.D</last_name>
    <phone>+86 512 67781856</phone>
    <email>chenjiasuzhou@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caixia Li</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 5, 2021</study_first_submitted>
  <study_first_submitted_qc>April 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Zanubrutinib, R-CHOP, Newly diagnosed Non-GCB DLBCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Zanubrutinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

